INZY - Inozyme Pharma GAAP EPS of -$1.78 beats by $0.03
2023-03-22 08:56:51 ET
- Inozyme Pharma press release ( NASDAQ: INZY ): FY GAAP EPS of -$1.78 beats by $0.03 .
- Cash, cash equivalents, and short-term investments were $127.9 million as of December 31, 2022. Based on its current plans, the Company anticipates its cash, cash equivalents, and short-term investments as of December 31, 2022, together with the additional $20.0 million borrowed on February 15, 2023 under its existing debt facility, will enable the Company to fund cash flow requirements into the fourth quarter of 2024.
For further details see:
Inozyme Pharma GAAP EPS of -$1.78 beats by $0.03